1[1]HarrisJR, Morrow M, Bonadonna G. Cancer of the breast, in Devita JR, Hellman S, Rosenberg SA(eds):Cancer Principle and Practice of Oncology[JM],ed 5. Philadelphia,JB Lippincott CO,1997:1264-1332.
2[2]Jordan VG, Morrwo M. An appraisal of strategies to reduce the incidence of breast cancer[J].Stem Cells,1993,11(4):252-262.
3[3]King MC, Rowell S, LoveSM. Inherited breastand ovarian cancer:What arethe risks? What are the choices?[J].JMMA,1993,269(15):1975-1980.
4[4]Morrow M.Pre-cancerous breast cancer lesions:implications forbreast cancer prevention trials[J].Int J Radiat Oncol Biol Phys, 1992,23(5):1071-1078.
5[5]Ottesen GL, Graversen HP, Blichert-Toft, et al. Lobular carcinoma in stiu of the female brest. The Danish Breast Cancer Cooperative Group:Short tem results of prospective nationwide study[J].Am J Surg Pathol,1993,17(1):14-21.
6[6]Bondy SML, Lustbsder ER, halabi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history[J].J Natl Cancer nst,1994,86(8):620-625.
7[7]Gail J, BrintonLA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually[J].J Natl Cancer Inst,1989,81(24):1879-1886.
8[8]Bostwick J 3d, Jones G. Why I Choose autogenous tissue in breast reconstruction[J].Clin Plast Surg,1994,21(2):165-175.
9[9]Fisher B, Costantino JP, Wickerham DL, etal. Tamoxifen for prevention of breast cancer:report of the national surgical adjuvant breast and bowel project P-1 sutdy[J].J Natl Cancer Inst,1998,90(18):1371-1388.
10[10]Morrow M, Quiet C, Hellman S, et al. Treatment selection in breast cancer:are our biases correct?[J] Proceedings of american society of clinical oncologists,1994,13:99-100.
7Sasaki Y, Kamata S, Saito K, et al.Pseudoangiomatous stromal hyperplasia (PASH) of the mammary gland: report of a case[J]. Surgery today, 2008, 38 (4): 340-343.
